MoonLake Immunotherapeutics News

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Diodes posted adjusted earnings of 28 cents

Benzinga00:44

MoonLake Immunotherapeutics Buy Rating Justified by Strong Clinical Execution and Financial Position

TipRanksMay 10 13:17

HC Wainwright & Co. : MoonLake (MLTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $100.00.

HC Wainwright & Co. : MoonLake (MLTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $100.00.

Zhitong FinanceMay 9 03:20

MoonLake Immunotherapeutics Earns Buy Rating: Advancing Clinical Programs and Strong Financial Position

TipRanksMay 8 18:26

MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham

MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham

Dow JonesMay 8 18:03

Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Ionis Pharmaceuticals (IONS) and Premier (PINC)

TipRanksMay 8 18:00

Needham Reiterates Buy on MoonLake, Maintains $66 Price Target

Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $66 price target.

BenzingaMay 8 17:53

MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes

Yahoo FinanceMay 8 09:02

Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Rocket Pharmaceuticals (RCKT)

TipRanksMay 8 03:30

MoonLake Q1 EPS $(0.22) Misses $(0.20) Estimate

MoonLake (NASDAQ:MLTX) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.20) by 10 percent. This is a 4.35 percent increase over losses of $(0.23) per s

BenzingaMay 7 20:09

MoonLake Immunotherapeutics | 10-Q: Quarterly report

Futu NewsMay 7 20:04 · Announcements

MoonLake Immunotherap 1Q Loss/Shr $0.22 >MLTX

MoonLake Immunotherap 1Q Loss/Shr $0.22 >MLTX

Dow JonesMay 7 20:00

MoonLake Immunotherapeutics | 10-K/A: Annual report (Amendment)

Futu NewsMay 7 19:59 · Announcements

MoonLake Immunotherapeutics' Sonelokimab Shows Promise in Psoriatic Arthritis and HS, Meriting a Buy Rating

TipRanksMay 2 23:45

Strong Buy Rating for MoonLake Immunotherapeutics Based on Promising Sonelokimab Clinical Trials and Market Potential

TipRanksApr 27 02:55

MoonLake Immunotherapeutics: A Promising Outlook With Sonelokimab's Potential in the HS Market

TipRanksApr 23 18:25

Buy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Clinical Results for Sonelokimab

TipRanksApr 23 00:35

MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co.

MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co.

Dow JonesApr 11 19:37

HC Wainwright & Co. : MoonLake (MLTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $100.00.

HC Wainwright & Co. : MoonLake (MLTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $100.00.

Zhitong FinanceApr 11 19:31

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake with a Buy and maintains $100 price target.

Analyst UpgradesApr 11 19:27